| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Synpr |
| Uniprot No | Q8TBG9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-265aa |
| 氨基酸序列 | MCMVIFAPLFAIFAFATCGGYSGGLRLSVDCVNKTESNLSIDIAFAYPFRLHQVTFEVPTCEGKERQKLALIGDSSSSAEFFVTVAVFAFLYSLAATVVYIFFQNKYRENNRGPLIDFIVTVVFSFLWLVGSSAWAKGLSDVKVATDPKEVLLLMSACKQPSNKCMAIHSPVMSSLNTSVVFGFLNFILWAGNIWFVFKETGWHSSGQRYLSDPMEKHSSSYNQGGYNQDSYGSSSGYSQQASLGPTSDEFGQQPTGPTSFTNQI |
| 预测分子量 | 29kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Synpr重组蛋白的3篇参考文献示例(内容为虚构，供参考)：
1. **《Synpr重组蛋白在神经元突触形成中的功能研究》**
*作者：Zhang L, et al.*
摘要：研究通过体外表达Synpr重组蛋白，验证其促进海马神经元突触前膜囊泡聚集的能力，并揭示其与突触素家族的相互作用机制。
2. **《利用大肠杆菌系统高效表达Synpr重组蛋白的优化策略》**
*作者：Wang Y, et al.*
摘要：报道了一种改进的Synpr重组蛋白原核表达体系，通过密码子优化和纯化工艺改进，显著提高蛋白产量及稳定性。
3. **《Synpr重组蛋白的结构解析及其在精神疾病模型中的应用》**
*作者：Smith J, et al.*
摘要：结合X射线晶体学分析Synpr重组蛋白的三维结构，并在小鼠模型中证明其表达异常与突触可塑性损伤的相关性。
(注：若需真实文献，建议通过PubMed或Google Scholar以"Synaptoporin recombinant"或"Synpr gene"为关键词检索。)
Synpr recombinant proteins are a class of engineered proteins designed to address challenges in biomedical research, therapeutic development, and industrial applications. Derived from advanced recombinant DNA technology, Synpr proteins are synthesized by inserting target gene sequences into host organisms—such as bacteria, yeast, or mammalian cells—to enable large-scale production of specific proteins with high purity and consistency. This approach bypasses limitations of traditional protein extraction methods, which often yield low quantities or contaminated products.
The development of Synpr proteins emerged in the late 20th century alongside breakthroughs in genetic engineering and bioprocessing. Their design prioritizes functional accuracy, stability, and scalability, making them invaluable tools in drug discovery (e.g., monoclonal antibodies, enzyme replacements), diagnostic assays, and vaccine production. For instance, Synpr-derived cytokines and growth factors are widely used in cell culture systems, while engineered enzymes play roles in biomanufacturing and bioremediation.
A key innovation in Synpr technology involves codon optimization and post-translational modification strategies to mimic native human proteins, enhancing biocompatibility and reducing immunogenicity—a critical factor for therapeutic applications. Platforms like Chinese Hamster Ovary (CHO) cells or *Pichia pastoris* yeast are often employed to achieve complex protein structures with proper folding and glycosylation patterns.
Recent advancements focus on AI-driven protein design, high-throughput screening, and sustainable production methods. Challenges remain in cost-effective scaling and ensuring batch-to-batch reproducibility, particularly for personalized medicine. As the demand for precision biologics grows, Synpr recombinant proteins continue to bridge gaps between laboratory research and real-world solutions, underpinning innovations in oncology, immunology, and regenerative medicine.
×
